- Home
- DEO vs TAK Comparison
DEO vs TAK Comparison
Compare DEO & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DEO
- TAK
- Stock Information
- Founded
- DEO 1886
- TAK 1781
- Country
- DEO United Kingdom
- TAK Japan
- Employees
- DEO N/A
- TAK N/A
- Industry
- DEO Beverages (Production/Distribution)
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- DEO Consumer Staples
- TAK Health Care
- Exchange
- DEO Nasdaq
- TAK Nasdaq
- Market Cap
- DEO 53.2B
- TAK 43.3B
- IPO Year
- DEO N/A
- TAK N/A
- Fundamental
- Price
- DEO $90.85
- TAK $14.52
- Analyst Decision
- DEO Strong Buy
- TAK
- Analyst Count
- DEO 2
- TAK 0
- Target Price
- DEO $109.00
- TAK N/A
- AVG Volume (30 Days)
- DEO 1.8M
- TAK 3.3M
- Earning Date
- DEO 08-14-2025
- TAK 10-30-2025
- Dividend Yield
- DEO 4.49%
- TAK 1.90%
- EPS Growth
- DEO N/A
- TAK N/A
- EPS
- DEO 1.06
- TAK 0.14
- Revenue
- DEO $20,245,000,000.00
- TAK $29,846,840,032.00
- Revenue This Year
- DEO $6.43
- TAK $0.01
- Revenue Next Year
- DEO $3.78
- TAK $0.49
- P/E Ratio
- DEO $85.75
- TAK $104.21
- Revenue Growth
- DEO N/A
- TAK N/A
- 52 Week Low
- DEO $86.57
- TAK $12.80
- 52 Week High
- DEO $132.34
- TAK $15.69
- Technical
- Relative Strength Index (RSI)
- DEO 43.76
- TAK 62.71
- Support Level
- DEO $90.14
- TAK $14.01
- Resistance Level
- DEO $91.79
- TAK $14.56
- Average True Range (ATR)
- DEO 1.40
- TAK 0.17
- MACD
- DEO -0.07
- TAK 0.08
- Stochastic Oscillator
- DEO 23.60
- TAK 95.50
About DEO Diageo plc
Formed in 1997 through the merger of Grand Metropolitan and Guinness, Diageo is the largest distiller globally by sales. Diageo acquired some of the Seagram assets in 2001, which gave it brands such as Captain Morgan rum and Crown Royal Canadian whisky. Since then, mergers and acquisitions have mostly been bolt-on in nature, plugging gaps in the company's product and geographic portfolio. The firm has also shed noncore brands over the years, including the majority of its wine assets in 2015.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.